I'm going for no T/O, but Neuren becoming a licensing and dividend powerhouse and continuing to churn out Phase 2 trials (and possibly Ph 3 trials) in dozens of new indications.Why does Neuren have to be bought out? Could happen, but is not the only worthwhile outcome I think.
I'm going for no T/O, but Neuren becoming a licensing and...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.08 |
Change
-0.050(0.38%) |
Mkt cap ! $1.683B | |||
| Open | High | Low | Value | Volume |
| $13.22 | $13.32 | $13.01 | $1.442M | 109.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 278 | $13.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.09 | 1137 | 11 |
View Market Depth
| Last trade - 12.02pm 21/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |